{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"condition":["colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2702727"],"location":["China"],"study_start_month":["2"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Real-world study of the efficacy and safety of bevacizumab for first-line and post-first-line treatment of advanced RAS mutated colorectal cancer","description":"Interventions: experimental group:chemotherapy combined with bevacizumab\nPrimary outcome(s): Progression-Free Survival;Overall Survival\nStudy Design: Sequential","dates":{"creation":"2021-02-15"},"accession":"2702727","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2100042553"]}}